Neurocrine Biosciences | NBIX - Attività Correnti





Attività Correnti Cambiamento Data
AbbVie USD 33.67B 140M 2026-06
Acadia Pharmaceuticals USD 1.22B 128.53M 2026-06
Agios Pharmaceuticals USD 717.67M 117.18M 2026-06
ALKERMES USD 1.52B 164.26M 2026-06
Alnylam Pharmaceuticals USD 5.11B 492.49M 2026-09
Amgen USD 34.96B 3.49B 2026-06
Biogen USD 7.58B 278.7M 2026-09
BioMarin Pharmaceutical USD 3.97B 633.45M 2026-06
Cytokinetics USD 1.21B 369.02M 2026-06
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Exelixis USD 1.25B 42.18M 2026-06
Gilead Sciences USD 16.55B 4.02B 2026-09
Halozyme Therapeutics USD 933.02M 70.01M 2026-06
Incyte USD 5.52B 505.2M 2026-09
Ionis Pharmaceuticals USD 2.49B 446.73M 2026-06
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Neurocrine Biosciences USD 1.64B 798.6M 2026-06
Pfizer USD 41.36B 1.46B 2026-06
Prothena USD 292.01M 47.19M 2026-06
Regeneron Pharmaceuticals USD 18.45B 236.8M 2026-06
Repligen USD 1.24B 41.43M 2026-09
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
Sarepta Therapeutics USD 2.22B 86.05M 2026-06
Teva Pharmaceutical Industries USD 13.76B 50M 2026-06
Ultragenyx Pharmaceutical USD 606M 51M 2026-06
Vertex Pharmaceuticals USD 12.54B 813.4M 2026-06